Can a depression drug tame the psychedelic trip without killing the benefits?

NCT ID NCT07210112

Not yet recruiting Symptom relief Sponsor: Centre Hospitalier St Anne Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding the antidepressant trazodone to psilocybin can reduce the intense psychedelic effects while keeping the mood-lifting benefits. 112 adults with treatment-resistant depression will receive either psilocybin alone, psilocybin plus a low or high dose of trazodone, or placebo. The main goal is to see if the combination improves depression scores after one month.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin and trazodone
What this could lead to: If it works, this could point toward a depression treatment that reduces severe symptoms without the intense psychedelic experience.
What could go wrong: This is an early proof-of-concept study with only 112 people. It may fail to show benefit, and the combination could still cause side effects or not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION - MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depressive Disorder, Treatment-Resistant major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESSION - MAJOR DEPRESSIVE DISORDER TREATMENT RESISTANT DEPRESSION (TRD)

Contacts and locations

Locations

GHU Paris Psychiatrie and Neurosciences

Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.